文献速递心力衰竭与心肌病

恩格列净对射血分数降低心衰患者健康相关生活质量的影响:EMPEROR-Reduced试验

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
PubMed 文献 · Eur Heart J · 2021-01-01

EMPEROR-Reduced试验的二次分析评估恩格列净对射血分数降低心衰患者患者报告结局的影响。结果显示,无论基线KCCQ-CSS三分位如何,恩格列净均降低心血管死亡或心衰住院风险;恩格列净在3、8、12个月改善KCCQ-CSS、总症状评分和总体总结评分,且更多患者获得≥5、10、15分改善,更少患者出现≥5分恶化。

要点

  • 恩格列净降低心血管死亡或心衰住院风险,不受基线KCCQ-CSS三分位影响。
  • 恩格列净在3、8、12个月改善KCCQ-CSS、总症状评分和总体总结评分。
  • 恩格列净组更多患者KCCQ-CSS改善≥5、10、15分,更少患者恶化≥5分。

核心结论

  • 恩格列净在基线健康状态范围内均降低心血管死亡或心衰住院风险。
  • 恩格列净改善多个域的健康状态,且获益在长期随访中持续。

研究设计与样本

  • EMPEROR-Reduced试验的二次分析。
  • 健康状态采用堪萨斯城心肌病问卷临床总结评分(KCCQ-CSS)评估。
  • 采用Cox比例风险模型分析基线KCCQ-CSS三分位对恩格列净疗效的影响。
  • 进行应答者分析评估KCCQ评分改善和恶化的比值比。

主要发现

  • 恩格列净降低主要结局(心血管死亡或心衰住院),基线KCCQ-CSS三分位对应的风险比分别为0.83(0.68-1.02)、0.74(0.58-0.94)和0.61(0.46-0.82)(<62.5、62.6-85.4、≥85.4分三分位),P-trend=0.10。
  • 恩格列净在3、8、12个月改善KCCQ-CSS、总症状评分和总体总结评分。
  • 3个月时,恩格列净组更多患者KCCQ-CSS改善≥5分(OR 1.20,1.05-1.37)、≥10分(OR 1.26,1.10-1.44)、≥15分(OR 1.29,1.12-1.48),更少患者恶化≥5分(OR 0.75,0.64-0.87)。
  • 这些获益在8和12个月时持续,其他KCCQ域结果相似。

临床怎么用

  • 对于射血分数降低心衰患者,恩格列净可改善健康相关生活质量,且不受基线健康状态影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. METHODS AND RESULTS: Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68-1.02), HR 0.74 (0.58-0.94), and HR 0.61 (0.46-0.82) for <62.5, 62.6-85.4, and ≥85.4 score tertiles, respectively; P-trend = 0.10]. Empagliflozin improved KCCQ-CSS, total symptom score, and overall summary score at 3, 8, and 12 months. More patients on empagliflozin had ≥5-point [odds ratio (OR) 1.20 (1.05-1.37)], 10-point [OR 1.26 (1.10-1.44)], and 15-point [OR 1.29 (1.12-1.48)] improvement and fewer had ≥5-point [OR 0.75 (0.64-0.87)] deterioration in KCCQ-CSS at 3 months. These benefits were sustained at 8 and 12 months and were similar for other KCCQ domains. CONCLUSION: Empagliflozin improved cardiovascular death or heart failure hospitalization risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03057977.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Butler J, Anker SD, Filippatos G, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021. PMID: 33420498. doi:10.1093/eurheartj/ehaa1007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。